Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of sacituzumab govitecan versus physician's choice therapy in metastatic or locally advanced unresectable urothelial carcinoma
CTR20211362Phase 3Completed
- Sponsor
- Everest Medicines
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan in transitional cell carcinoma (TCC), sponsored by Everest Medicines. Started Aug 2021; status: completed.
02
Drugs
sacituzumab govitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20211362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211362.